Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / Ordinary shares, nominal value 0.002 GBP per share
Symbol
CNTA on Nasdaq
Shares outstanding
145,993,531
Price per share
$24.89
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
143,756,351
Total reported value
$3,595,234,186
% of total 13F portfolios
0.01%
Share change
+15,431,787
Value change
+$388,743,626
Number of holders
146
Price from insider filings
$24.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 10% +24% $364,034,431 +$93,724,350 14,555,555 +35% Avoro Capital Advisors LLC 31 Dec 2025
FMR LLC 12% +23% $275,104,823 +$52,642,399 10,999,793 +24% FMR LLC 30 Jan 2026
Adage Capital Management, L.P. 7.5% +20% $243,348,750 +$39,576,000 10,035,000 +19% Adage Capital Management, L.P. 30 Sep 2025
General Atlantic Cooperatief U.A. 5% -23% $180,192,368 -$56,624,900 7,366,818 -24% General Atlantic Cooperatief U.A. 25 Nov 2025

As of 31 Dec 2025, 146 institutional investors reported holding 143,756,351 shares of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA). This represents 98% of the company’s total 145,993,531 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Medicxi Ventures Management (Jersey) Ltd 14% 19,963,157 0% 60% $499,278,557
Avoro Capital Advisors LLC 10% 14,555,555 +35% 3.6% $364,034,431
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.7% 11,281,741 +12% 0.43% $282,156,342
Index Venture Life Associates VI Ltd 6.8% 9,961,789 0% 100% $249,144,343
FMR LLC 6.1% 8,961,939 +43% 0.01% $224,138,094
GENERAL ATLANTIC, L.P. 4.2% 6,117,715 -37% 5.3% $153,004,052
FARALLON CAPITAL MANAGEMENT LLC 3.7% 5,377,068 +24% 0.78% $134,480,471
TCG Crossover Management, LLC 2.9% 4,286,480 +37% 3.5% $107,204,865
JANUS HENDERSON GROUP PLC 2.8% 4,093,608 -24% 0.05% $102,393,318
Siren, L.L.C. 2.8% 4,027,517 +25% 3% $100,728,200
PRICE T ROWE ASSOCIATES INC /MD/ 2.7% 3,927,343 -18% 0.01% $98,223,000
EcoR1 Capital, LLC 2.1% 3,115,000 +466% 3.6% $77,906,150
PERCEPTIVE ADVISORS LLC 2% 2,917,634 -5.9% 1.3% $72,970,026
FRANKLIN RESOURCES INC 1.6% 2,368,381 -7.4% 0.01% $59,233,201
FEDERATED HERMES, INC. 1.6% 2,342,139 +34% 0.1% $58,576,896
First Light Asset Management, LLC 1.6% 2,278,940 -37% 4.4% $56,996,289
BRAIDWELL LP 1.5% 2,188,320 1.8% $54,729,883
Deep Track Capital, LP 1.4% 2,000,000 1.1% $50,020,000
MILLENNIUM MANAGEMENT LLC 1.3% 1,870,671 +107% 0.03% $46,785,482
RTW INVESTMENTS, LP 1.2% 1,790,837 -22% 0.45% $44,788,833
MAVERICK CAPITAL LTD 1.1% 1,643,724 0.44% $41,109,537
Foresite Capital Management VI LLC 0.93% 1,364,019 +3.8% 10% $34,114,115
Cormorant Asset Management, LP 0.91% 1,325,000 -31% 1.9% $33,138,250
Capital World Investors 0.79% 1,158,699 +69% 0% $28,979,062
STEMPOINT CAPITAL LP 0.79% 1,154,114 +76% 5% $28,864,391

Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 143,756,351 $3,595,234,186 +$388,743,626 $25.01 146
2025 Q3 128,332,503 $3,111,987,564 +$147,803,679 $24.25 124
2025 Q2 123,569,478 $1,623,678,828 -$30,690,539 $13.14 117
2025 Q1 124,913,742 $1,797,461,231 -$6,439,160 $14.38 130
2024 Q4 124,413,136 $2,083,915,345 +$72,898,202 $16.75 114
2024 Q3 108,571,980 $1,737,489,847 +$315,516,266 $15.99 101
2024 Q2 86,506,981 $781,158,600 +$108,671,569 $9.03 79
2024 Q1 74,395,267 $840,663,455 +$66,659,727 $11.30 69
2023 Q4 71,279,084 $567,382,245 +$15,317,885 $7.96 56
2023 Q3 72,578,425 $469,582,127 +$14,480,766 $6.47 46
2023 Q2 70,339,619 $435,403,089 +$25,413,534 $6.19 43
2023 Q1 66,895,058 $257,540,618 +$13,125,714 $3.85 42
2022 Q4 62,684,642 $194,353,719 +$5,918,047 $3.10 41
2022 Q3 71,808,783 $288,649,039 -$842,289 $4.02 41
2022 Q2 71,775,040 $349,577,531 -$37,633,222 $4.87 40
2022 Q1 74,581,035 $669,057,512 +$23,146,015 $8.97 40
2021 Q4 71,873,880 $807,766,000 +$18,577,946 $11.26 46
2021 Q3 52,983,439 $881,813,000 +$147,088,157 $16.70 38
2021 Q2 47,409,892 $1,045,414,000 +$1,045,413,999 $22.21 49